NO317660B1 - Anvendelse av bradykininantagonister i kombinasjon med minst ett ytterligere antivirusmiddel for fremstilling av legemidler for behandling av virussykdommer. - Google Patents

Anvendelse av bradykininantagonister i kombinasjon med minst ett ytterligere antivirusmiddel for fremstilling av legemidler for behandling av virussykdommer. Download PDF

Info

Publication number: NO317660B1
Authority: NO; Norway
Prior art keywords: substituted; aryl; hydrogen; alkyl; residue
Prior art date: 1993-12-31

Application number

NO19945094A

Other languages

English (en)

Norwegian (no)

Other versions

NO945094D0 (no

NO945094L (no

Inventor

Fred Lembeck

Gerhard Breipohl

Irvin Winkler

Jochen Knolle

Klaus Wirth

Stephan Henke

Original Assignee

Hoechst Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-12-31

Filing date

1994-12-30

Publication date

2004-11-29

1994-12-30 Application filed by Hoechst Ag filed Critical Hoechst Ag

1994-12-30 Publication of NO945094D0 publication Critical patent/NO945094D0/no

1995-07-03 Publication of NO945094L publication Critical patent/NO945094L/no

2004-11-29 Publication of NO317660B1 publication Critical patent/NO317660B1/no

Links

239000003152 bradykinin antagonist Substances 0.000 title claims abstract description 21
238000011282 treatment Methods 0.000 title claims abstract description 15
201000010099 disease Diseases 0.000 title claims abstract description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 5
230000003612 virological effect Effects 0.000 title claims abstract 3
239000003443 antiviral agent Substances 0.000 title claims description 9
239000003814 drug Substances 0.000 title claims description 7
238000004519 manufacturing process Methods 0.000 title claims description 3
229940079593 drug Drugs 0.000 title description 5
150000003839 salts Chemical class 0.000 claims abstract description 5
238000011321 prophylaxis Methods 0.000 claims abstract description 4
-1 carboxy, amino Chemical group 0.000 claims description 34
229910052739 hydrogen Inorganic materials 0.000 claims description 24
239000001257 hydrogen Substances 0.000 claims description 24
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
238000002360 preparation method Methods 0.000 claims description 15
229910052736 halogen Inorganic materials 0.000 claims description 10
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
UYRCOTSOPWOSJK-JXTBTVDRSA-N bradykinin antagonist Chemical compound C1C2=CC=CC=C2CC1[C@@H](NC(=O)C(CO)NC(=O)C(NC(=O)CNC(=O)[C@H]1N(C[C@H](O)C1)C(=O)C1N(CCC1)C(=O)C(CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=N)CCCCCCC(=N)N[C@H](CCCNC(N)=N)C(=O)NC(CCCNC(N)=N)C(=O)N1C(CCC1)C(=O)N1[C@@H](C[C@@H](O)C1)C(=O)NCC(=O)NC(C1CC2=CC=CC=C2C1)C(=O)NC(CO)C(=O)N[C@H](C1CC2=CC=CC=C2C1)C(=O)N1C2CCCCC2CC1C(=O)NC(CCCNC(N)=N)C(O)=O)C1CC2=CC=CC=C2C1)C(=O)N1C2CCCCC2CC1C(=O)NC(CCCNC(=N)N)C(O)=O UYRCOTSOPWOSJK-JXTBTVDRSA-N 0.000 claims description 8
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 8
150000001875 compounds Chemical class 0.000 claims description 8
150000002367 halogens Chemical class 0.000 claims description 8
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 7
125000005915 C6-C14 aryl group Chemical group 0.000 claims description 6
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 6
125000004429 atom Chemical group 0.000 claims description 6
125000004432 carbon atom Chemical group C* 0.000 claims description 6
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
125000004356 hydroxy functional group Chemical group O* 0.000 claims description 6
230000007935 neutral effect Effects 0.000 claims description 6
125000005544 phthalimido group Chemical group 0.000 claims description 6
241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 5
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 4
125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
230000002378 acidificating effect Effects 0.000 claims description 4
125000001931 aliphatic group Chemical group 0.000 claims description 4
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 4
125000001072 heteroaryl group Chemical group 0.000 claims description 4
FXHCFPUEIDRTMR-UHFFFAOYSA-N hydron;1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;chloride Chemical compound Cl.C1=CC=C2CNC(C(=O)O)CC2=C1 FXHCFPUEIDRTMR-UHFFFAOYSA-N 0.000 claims description 4
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 4
125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims description 4
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 3
125000003118 aryl group Chemical group 0.000 claims description 3
125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims description 2
208000007514 Herpes zoster Diseases 0.000 claims description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
150000001413 amino acids Chemical class 0.000 claims description 2
125000003435 aroyl group Chemical group 0.000 claims description 2
125000004391 aryl sulfonyl group Chemical group 0.000 claims description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 2
125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
125000004093 cyano group Chemical group *C#N 0.000 claims description 2
125000000623 heterocyclic group Chemical group 0.000 claims description 2
150000002431 hydrogen Chemical class 0.000 claims description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
229910052757 nitrogen Inorganic materials 0.000 claims description 2
229910052760 oxygen Inorganic materials 0.000 claims description 2
239000001301 oxygen Substances 0.000 claims description 2
229910052717 sulfur Inorganic materials 0.000 claims description 2
239000011593 sulfur Substances 0.000 claims description 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
239000002253 acid Substances 0.000 claims 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
QURWXBZNHXJZBE-SKXRKSCCSA-N icatibant Chemical compound NC(N)=NCCC[C@@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2SC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@H](CC3=CC=CC=C3C2)C(=O)N2[C@@H](C[C@@H]3CCCC[C@@H]32)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C[C@@H](O)C1 QURWXBZNHXJZBE-SKXRKSCCSA-N 0.000 description 11
108700023918 icatibant Proteins 0.000 description 11
229960004150 aciclovir Drugs 0.000 description 9
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 9
206010040882 skin lesion Diseases 0.000 description 7
231100000444 skin lesion Toxicity 0.000 description 7
241001465754 Metazoa Species 0.000 description 6
241000700588 Human alphaherpesvirus 1 Species 0.000 description 5
238000000034 method Methods 0.000 description 5
239000000243 solution Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
241000699670 Mus sp. Species 0.000 description 4
241000700605 Viruses Species 0.000 description 4
230000001476 alcoholic effect Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000006071 cream Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
208000019022 Mood disease Diseases 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000011284 combination treatment Methods 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
238000011835 investigation Methods 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
101800004538 Bradykinin Proteins 0.000 description 2
102400000967 Bradykinin Human genes 0.000 description 2
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
230000001143 conditioned effect Effects 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000499 gel Substances 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
239000003701 inert diluent Substances 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
229960002555 zidovudine Drugs 0.000 description 2
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
102000010183 Bradykinin receptor Human genes 0.000 description 1
108050001736 Bradykinin receptor Proteins 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
244000165918 Eucalyptus papuana Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
206010019973 Herpes virus infection Diseases 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
229920004011 Macrolon® Polymers 0.000 description 1
JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000019486 Sunflower oil Nutrition 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
125000001980 alanyl group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
239000012159 carrier gas Substances 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000003026 cod liver oil Substances 0.000 description 1
235000012716 cod liver oil Nutrition 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
229960004716 idoxuridine Drugs 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229960001627 lamivudine Drugs 0.000 description 1
JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000014380 magnesium carbonate Nutrition 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
235000012245 magnesium oxide Nutrition 0.000 description 1
MSWIFFGHKBTPMY-VFUQPONKSA-L magnesium;(e)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O.CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O MSWIFFGHKBTPMY-VFUQPONKSA-L 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
229940100656 nasal solution Drugs 0.000 description 1
238000002663 nebulization Methods 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000007921 spray Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000002600 sunflower oil Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
229940093257 valacyclovir Drugs 0.000 description 1
230000002227 vasoactive effect Effects 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
229960003636 vidarabine Drugs 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/043—Kallidins; Bradykinins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/18—Kallidins; Bradykinins; Related peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO19945094A 1993-12-31 1994-12-30 Anvendelse av bradykininantagonister i kombinasjon med minst ett ytterligere antivirusmiddel for fremstilling av legemidler for behandling av virussykdommer. NO317660B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE4345062A DE4345062A1 (de)	1993-12-31	1993-12-31	Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung von Viruserkrankungen

Publications (3)

Publication Number	Publication Date
NO945094D0 NO945094D0 (no)	1994-12-30
NO945094L NO945094L (no)	1995-07-03
NO317660B1 true NO317660B1 (no)	2004-11-29

Family

ID=6506576

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19945094A NO317660B1 (no)	1993-12-31	1994-12-30	Anvendelse av bradykininantagonister i kombinasjon med minst ett ytterligere antivirusmiddel for fremstilling av legemidler for behandling av virussykdommer.

Country Status (21)

Country	Link
US (1)	US5789383A (uk)
EP (1)	EP0661058B1 (uk)
JP (1)	JP3828593B2 (uk)
KR (1)	KR100358822B1 (uk)
CN (1)	CN1119171C (uk)
AT (1)	ATE255417T1 (uk)
AU (1)	AU696629B2 (uk)
BR (1)	BR9405308A (uk)
CA (1)	CA2138933C (uk)
DE (2)	DE4345062A1 (uk)
DK (1)	DK0661058T3 (uk)
ES (1)	ES2211874T3 (uk)
FI (1)	FI117320B (uk)
HU (1)	HU226374B1 (uk)
IL (1)	IL112183A (uk)
MY (1)	MY112888A (uk)
NO (1)	NO317660B1 (uk)
PT (1)	PT661058E (uk)
RU (1)	RU2228195C2 (uk)
UA (1)	UA41326C2 (uk)
ZA (1)	ZA9410381B (uk)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2737408B1 (fr)	1995-07-31	1997-09-05	Oreal	Utilisation d'un antagoniste de bradykinine dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
DE19612067A1 (de) *	1996-03-27	1997-10-02	Hoechst Ag	Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung von chronisch fibrogenetischen Lebererkrankungen und akuten Lebererkrankungen
WO2016170382A1 (en) *	2015-04-23	2016-10-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Pharmaceutical compositions comprising a bradykinin 2 receptor antagonist for prevention or treatment of impaired skin wound healing
CN109563144B (zh)	2016-06-01	2023-03-28	雅斯娜	化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE63490B1 (en) *	1988-11-24	1995-05-03	Hoechst Ag	Peptides having bradykinin antagonist action
MX9100717A (es) *	1990-08-24	1992-04-01	Syntex Inc	Antagonistas de la bradiquinina
CZ203693A3 (en) *	1991-04-01	1994-07-13	Cortech	Bradykinin antagonists
CA2106762C (en) *	1991-04-19	2000-10-10	Donald J. Kyle	Bradykinin antagonist peptides
ES2123556T3 (es) *	1991-04-19	1999-01-16	Scios Nova Inc	Peptidos de tipo bradiquinina.
US5240694A (en) *	1991-09-23	1993-08-31	University Of Virginia	Combined antiviral and antimediator treatment of common colds
AU680870B2 (en) *	1993-04-28	1997-08-14	Astellas Pharma Inc.	New heterocyclic compounds

1993
- 1993-12-31 DE DE4345062A patent/DE4345062A1/de not_active Withdrawn
1994
- 1994-12-22 CA CA2138933A patent/CA2138933C/en not_active Expired - Lifetime
- 1994-12-23 HU HU9403783A patent/HU226374B1/hu unknown
- 1994-12-27 DK DK94120774T patent/DK0661058T3/da active
- 1994-12-27 DE DE59410340T patent/DE59410340D1/de not_active Expired - Lifetime
- 1994-12-27 ES ES94120774T patent/ES2211874T3/es not_active Expired - Lifetime
- 1994-12-27 EP EP94120774A patent/EP0661058B1/de not_active Expired - Lifetime
- 1994-12-27 PT PT94120774T patent/PT661058E/pt unknown
- 1994-12-27 AT AT94120774T patent/ATE255417T1/de active
- 1994-12-28 JP JP32690294A patent/JP3828593B2/ja not_active Expired - Lifetime
- 1994-12-29 US US08/366,598 patent/US5789383A/en not_active Expired - Lifetime
- 1994-12-29 BR BR9405308A patent/BR9405308A/pt not_active Application Discontinuation
- 1994-12-29 RU RU94045140/15A patent/RU2228195C2/ru active
- 1994-12-29 UA UA94129268A patent/UA41326C2/uk unknown
- 1994-12-29 IL IL11218394A patent/IL112183A/en not_active IP Right Cessation
- 1994-12-29 AU AU81791/94A patent/AU696629B2/en not_active Expired
- 1994-12-29 CN CN94113434A patent/CN1119171C/zh not_active Expired - Lifetime
- 1994-12-29 ZA ZA9410381A patent/ZA9410381B/xx unknown
- 1994-12-29 MY MYPI94003551A patent/MY112888A/en unknown
- 1994-12-30 NO NO19945094A patent/NO317660B1/no not_active IP Right Cessation
- 1994-12-30 KR KR1019940039312A patent/KR100358822B1/ko active IP Right Grant
1995
- 1995-01-02 FI FI950010A patent/FI117320B/fi not_active IP Right Cessation

Also Published As

Publication number	Publication date
FI950010A (fi)	1995-07-01
ZA9410381B (en)	1995-08-29
EP0661058A1 (de)	1995-07-05
HU9403783D0 (en)	1995-02-28
DK0661058T3 (da)	2004-04-05
RU94045140A (ru)	1996-10-20
JPH07206703A (ja)	1995-08-08
AU8179194A (en)	1995-07-13
JP3828593B2 (ja)	2006-10-04
HUT71422A (en)	1995-11-28
EP0661058B1 (de)	2003-12-03
FI117320B (fi)	2006-09-15
DE59410340D1 (de)	2004-01-15
IL112183A (en)	2001-01-11
NO945094D0 (no)	1994-12-30
KR100358822B1 (ko)	2003-01-24
PT661058E (pt)	2004-04-30
CA2138933A1 (en)	1995-07-01
ATE255417T1 (de)	2003-12-15
AU696629B2 (en)	1998-09-17
KR950016779A (ko)	1995-07-20
CN1119171C (zh)	2003-08-27
BR9405308A (pt)	1995-09-19
RU2228195C2 (ru)	2004-05-10
HU226374B1 (en)	2008-10-28
NO945094L (no)	1995-07-03
US5789383A (en)	1998-08-04
ES2211874T3 (es)	2004-07-16
FI950010A0 (fi)	1995-01-02
IL112183A0 (en)	1995-03-15
UA41326C2 (uk)	2001-09-17
CA2138933C (en)	2010-02-23
CN1108138A (zh)	1995-09-13
MY112888A (en)	2001-10-31
DE4345062A1 (de)	1995-07-13

Publication	Publication Date	Title
NO321380B1 (no)	2006-05-02	Heptapeptid analog med oksytocinantagonistaktivitet, fremgangsmate ved fremstilling derav samt anvendelse derav til fremstilling av medikamenter.
RU2008146733A (ru)	2010-06-10	Новый подход к лечению повышенного внутриглазного давления
JPH08245417A (ja)	1996-09-24	鼻内投与のための薬学的非無機塩類液剤
CN109152810A (zh)	2019-01-04	用于预防和治疗杜氏肌肉萎缩症的方法和组合物
NO317660B1 (no)	2004-11-29	Anvendelse av bradykininantagonister i kombinasjon med minst ett ytterligere antivirusmiddel for fremstilling av legemidler for behandling av virussykdommer.
US20090143415A1 (en)	2009-06-04	Tetrodotoxin And Its Derivatives For The Treatment Of Central-Nervously Derived Neuropathic Pain
JP2007500693A (ja)	2007-01-18	移植片拒絶反応を予防するための合成ペプチドコポリマーを含む併用療法
RU2013103487A (ru)	2014-07-27	Вакцинотерапия неоваскуляризации сосудистой оболочки глаза
US6245736B1 (en)	2001-06-12	Use of peptidic bradykinin antagonists for the treatment and prevention of Alzheimer's disease
AU677290B2 (en)	1997-04-17	Use of bradykinin antagonists for the preparation of a medicament for the prophylaxis or treatment of arteriosclerosis
KR101838759B1 (ko)	2018-03-14	점안제
US20080194470A1 (en)	2008-08-14	Nim811 In Cerebral Ischemia and Brain and Spinal Cord Injury
EP0537291A1 (en)	1993-04-21	Method of treating nausea and emesis related to motion sickness
US20210032304A1 (en)	2021-02-04	Fibroblast growth factor analogs and uses thereof
WO2023150791A1 (en)	2023-08-10	Peptides and methods of use thereof in treating ocular disorders
EP1390055B1 (en)	2005-11-23	Tripeptide derivatives for the treatment of postlesional diseases of the nervous system
CN118831167A (zh)	2024-10-25	用于治疗脑血管疾病与免疫系统紊乱的药物及其制备方法与应用
EP0488041A2 (en)	1992-06-03	A pharmaceutical composition for cytomegalovirus infection
WO1988004926A1 (en)	1988-07-14	Nasal delivery of amino acids
KR20050105447A (ko)	2005-11-04	골관절염을 치료하기 위한 브래디키닌-ｂ2 수용체 길항제의용도
EP1853268A1 (en)	2007-11-14	Use of sodium channel blockers and their analogues for the treatment of nicotine dependency
DE3727138A1 (de)	1989-02-23	Verwendung von atrionatriuretischem faktor (anf), dessen teilsequenzen und analoga zur behandlung von herzerkrankungen
UA28715U (en)	2007-12-25	Method for treating headache or migraine
MX2007005512A (es)	2008-10-03	Inhibidores de deacetilasa de histona y metodos de uso

Legal Events

Date	Code	Title	Description
2015-01-12	MK1K	Patent expired